CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.

Also called NCT03998163

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03998163
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03998163. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-06 (actual); primary completion 2020-02-26 (actual). Results posted on 2021-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Condition
Uremic Pruritus
Intervention (Drug)
CR845 0.5 mcg/kg
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03998163
Content hash
ef9203b734333cb0eed374095e166498fc87dfe46abebf7dc5596bd40590a2b1